GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4960)

  • GC80883 structure
    GC80883Thalidomide-O-amide-C5-NH2 hydrochloride
    CAS: 2716130-28-6
    Purity: >95.50%

    Thalidomide-O-amide-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology [1] [2] .

  • GC80884 structure
    GC80884CXJ2080
    Purity: >98.00%

    CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC 50 of 0.88 nM.

  • GC80885 structure
    GC80885PROTAC CDK6 Degrader 1
    Purity: >98.50%

    PROTAC CDK6 Degrader 1 (compound 48a) is a potent and selective PROTAC CDK6 degrader with a DC 50 of 0.037 μM.

  • GC80887 structure
    GC80887MA203
    Purity: >98.00%

    MA203 is a selective CHK1 PROTAC degrader.

  • GC80888 structure
    GC80888PROTAC PLK1 Degrader-2
    Purity: >99.00%

    PROTAC PLK1 Degrader-2 is a peptide-based N-end rule PLK1 mini-PROTAC.

  • GC80890 structure
    GC80890NEK7 degrader-3
    CAS: 3119435-52-5
    Purity: >98.00%

    NEK7 degrader-3 is an orally active and brain-penetrant NEK7 molecular glue degrader with a DC 50 of 33.1 nM.

  • GC80891 structure
    GC80891NK7-902 diTFA
    Purity: >99.50%

    NK7-902 diTFA is a selective and orally active CRBN-dependent NEK7 molecular glue degrader with K d values of 1.5 and 2.6 μM for hNEK7 and mNEK7.

  • GC80916 structure
    GC80916ZX079
    CAS: 3124583-65-6
    Purity: >98.00%

    ZX079 is a dual BRD4 and CBP PROTAC degrader with a BRD4 DC 50 value of 0.035 nM and a CBP DC 50 value of < 0.02 nM.

  • GC80917 structure
    GC80917LD-110 trihydrochloride
    Purity: >98.00%

    LD-110 trihydrochloride is a highly efficient and effective LSD1 PROTAC degrader ( DC 50 = 0.44 μM).

  • GC80918 structure
    GC80918dCBP-30
    Purity: >98.00%

    dCBP-30 is an orally active, selective and dual-acting CBP/p300 PROTAC degrader with DC 50 values of 0.05 nM (CBP) and 0.04 nM (p300), respectively.

  • GC80920 structure
    GC80920PROTAC PARP2 degrader-1
    CAS: 2925182-32-5
    Purity: >95.50%

    PROTAC PARP2 degrader-1 is an orally active PARP2 PROTAC degrader with a DC 50 of 2 μM.

  • GC80922 structure
    GC80922PROTAC HDAC6 degrader 7
    Purity: >98.00%

    PROTAC HDAC6 degrader 7 is an orally active, highly efficient, and selective PROTAC degrader targeting histone deacetylase 6 ( HDAC6 ) ( IC 50 = 118 nM).

  • GC80940 structure
    GC80940dIRF4-2
    CAS: 3136609-62-3
    Purity: >99.00%

    dIRF4-2 is a selective IRF4 PROTAC degrader with a DC 50 value of 2.2 μM.

  • GC80942 structure
    GC80942IRF4 ligand-1
    CAS: 3113827-15-6
    Purity: >99.00%

    IRF4 ligand-1 is an IRF4 ligand that can be used for the synthesis of PROTACs, such as dIRF4-2 [1] .

  • GC80943 structure
    GC80943KT-474 hydrochloride
    CAS: 2751703-31-6
    Purity: >98.00%

    KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects.

  • GC80944 structure
    GC80944PROTAC BCL6 Degrader-3
    CAS: 3005272-58-9
    Purity: >99.50%

    PROTAC BCL6 Degrader-3 (compound 92) is a BCL6 PROTAC degrader.

  • GC80945 structure
    GC80945APH02174 hemiformic
    Purity: >98.00%

    APH02174 hemiformic is a highly selective and orally active IRAK4 PROTAC degrader with the DC 50 of 4.01 nM in THP-1 cells.

  • GC80946 structure
    GC80946PROTAC JAK1/2 degrader-1
    Purity: >99.00%

    PROTAC JAK1/2 degrader-1 is an orally active JAK1 / JAK2 PROTAC degrader, with DC 50 values of 1.4 μM and 0.92 μM against JAK1 and JAK2, respectively.

  • GC81022 structure
    GC81022JWZ-8-103
    CAS: 3110272-60-8
    Purity: >98.00%

    JWZ-8-103 is an orally active analog of PRLX-93936 and a molecular glue targeting TRIM21.

  • GC81024 structure
    GC81024PROTAC RNF4 degrader-1
    Purity: >98.00%

    PROTAC RNF4 degrader-1 is a RNF4 PROTAC degrader ( K d = 64.5 nM) that degrades RNF4 via the ubiquitin-proteasome system.

  • GC81025 structure
    GC81025PSP-0119
    CAS: 3104855-98-0
    Purity: >98.50%

    PSP-0119 is a highly efficient and effective PROTAC degrader targeting IRAK4 ( IC 50 = 2.83 nM).

  • GC81026 structure
    GC81026PROTAC SKP2 Degrader-1
    CAS: 3120650-15-6
    Purity: >99.50%

    PROTAC SKP2 Degrader-1 is a PROTAC degrader targeting SKP2, with a K d value of 6.28 μM.

  • GC81027 structure
    GC81027PROTAC HIF-1α degrader-2
    CAS: 3095636-64-6
    Purity: >98.00%

    PROTAC HIF-1α degrader-2 is a highly efficient and selective PROTAC degrader targeting HIF-1α. PROTAC HIF-1α degrader-2 promotes HIF-1α degradation via the ubiquitin-proteasome pathway by facilitating the formation of a HIF-1α/VHL ternary complex.

  • GC81040 structure
    GC81040VVD 065
    CAS: 3034876-85-9
    Purity: >99.50%

    VVD 065 is an orally active KEAP1 -dependent NRF2 molecular glue degrader with a KEAP1 K D of 65 nM.